TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19011227
Drug: 10-minute lymphatic
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-minute lymphatic treatment
Study: 12824973
Drug: Oral contraceptive/clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive/clomiphene citrate
Study: 1975324
Drug: Local instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local instillation of hyperosmolar glucose solution
Study: 730416
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg)
Study: 29812
Drug: Hydrochlorthiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorthiazide (50 mg)
Study: 29812
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Amiloride and Hydrochlorthiazide (50 + 5 mg)
Study: 28542805
Drug: Higher hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Higher hydrocortisone (HCT) dose (0.4-0.6 mg/kg body weight)
Study: 28542805
Drug: Lower hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lower hydrocortisone (HCT) dose (0.2-0.3 mg/kg body weight)
Study: 23524089
Drug: Diltiazem (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0 mg, 30 mg, 60 mg, 120 mg)
Study: 23524089
Drug: Verapamil (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0 mg, 30 mg, 60 mg, 120 mg)
Study: 23524089
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg) with naloxone
Study: 23524089
Drug: Verapamil (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (60 mg) with naloxone
Study: 23524089
Drug: Verapamil (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (60 mg)
Study: 19592625
Drug: Albiglutide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide (30 mg weekly, 50 mg biweekly, 100 mg monthly)
Study: 9766261
Drug: Octreotide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50 mcg) administered through continuous subcutaneous night infusion from midnight to 08:00 at increasing rate between 03:00 and 08:00 h
Study: 9766261
Drug: Octreotide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50 mcg) administered through subcutaneous injections at 20:00, 22:00, and 24:00 h
Study: 7828258
Drug: Oral ephedrine
Normalized name: ephedrine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ephedrine 30 mg, orally, 30 min before subarachnoid block
Study: 3046593
Drug: Combined non‐specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined non‐specific and specific immunotherapy (BCG and neuraminidase‐treated autologous tumour cells) over a 2 year programme
Study: 28300812
Drug: naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone 50 mg/day + guanfacine 1 mg/day (N+G)
Study: 26525620
Drug: naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone 50 mg/day + guanfacine placebo (N+GP)
Study: 26525620
Drug: naltrexone placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone placebo + guanfacine (NP+G)
Study: 19132200
Drug: Heparin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin prophylaxis prior to enrollment
Study: 15159320
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day UDCA for 21 days
Study: 15159320
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day UDCA for 21 days
Study: 15159320
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day UDCA for 21 days
Study: 9572636
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (1 cc s.c.)
Study: 8147095
Drug: Purified hemagglutinin
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified hemagglutinin antigen (HA) 7.5 micrograms/0.25 ml
Study: 8147095
Drug: Purified hemagglutinin
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified hemagglutinin antigen (HA) 22.5 micrograms/0.25 ml
Study: 8147095
Drug: Purified hemagglutinin
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified hemagglutinin antigen (HA) 67.5 micrograms/0.25 ml
Study: 8147095
Drug: Standard split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard split product vaccine (ST) 22.5 micrograms/ml
Study: 8147095
Drug: Purified hemagglutinin
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified hemagglutinin antigen (HA) highest dose
Study: 8147095
Drug: Equivalent dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent dose of HA vaccine
Study: 29329957
Drug: SAB-301 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAB-301 (1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 50 mg/kg)
Study: 29329957
Drug: SAB-301 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAB-301 (50 mg/kg)
Study: 26149465
Drug: EA 40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA 40,000 U subcutaneously once weekly
Study: 26149465
Drug: DA 500
Normalized name: Xeloda 500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA 500 mcg every 3 weeks
Study: 23880655
Drug: Sugar-free Red
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free Red Bull (SF-RB) containing caffeine (160 mg) and taurine (2000 mg)
Study: 23880655
Drug: Caffeine only
Normalized name: Caffeine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine only drink (160 mg)
Study: 20608874
Drug: HIV-1 gp120
Normalized name: HIV-1 gp120 Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 gp120 vaccine
Study: 12780402
Drug: Timolol maleate/latanoprost
Normalized name: timolol maleate/latanoprost/PF 0.5 %-0.005 % OPHTHALMIC DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol maleate/latanoprost fixed combination (TLFC) given once each evening
Study: 12780402
Drug: Brimonidine and
Normalized name: brimonidine and ripasudil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine and timolol solution given twice daily
Study: 9359537
Drug: Catheter-based revascularization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-based revascularization and conventional care (including lipid-lowering therapy if prescribed)
Study: 8239105
Drug: Continuous nebulization
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulization of albuterol (10 mg nebulized in 70 mL over two hours)
Study: 8239105
Drug: Intermittent nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nebulization of albuterol (2.5 mg at 30, 60, 90, and 120 minutes after initial treatment)
Study: 4027764
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg X kg‐1 of alpha‐tocopheryl acetate intramuscularly before anaesthesia (neonates)
Study: 4027764
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg X kg‐1 of alpha‐tocopheryl acetate orally for three days before anaesthesia (Group 2 infants)
Study: 4027764
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg X kg‐1 of alpha‐tocopheryl acetate intramuscularly three hours before anaesthesia (Group 3 infants)
Study: 29865227
Drug: Ferulic acid
Normalized name: Ferulic acid
DrugBank: Ferulic acid (DB07767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferulic acid (1000 mg daily)
Study: 26566754
Drug: Oral pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin 300 mg
Study: 24836866
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every month for the first 3 months, followed by every 2 months
Study: 22349989
Drug: RVX-208 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVX-208 100 mg bid for 24 weeks
Study: 22349989
Drug: RVX-208 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVX-208 100 mg bid for 26 weeks
Study: 18657831
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% phenylephrine drops
Study: 14671144
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (low dose: 30 mU/m2.min, high dose: 200 mU/m2.min) during recombinant human FSH (r-hFSH) administration
Study: 14671144
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/d) treatment for 5 months
Study: 14671144
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment with high-dose insulin infusion
Study: 7916925
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg OKT3
Study: 1453598
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg or 10 mg OKT3
Study: 7916925
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg OKT3
Study: 3841206
Drug: Diflunisal 1000
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal 1000 mg once daily for 14 days
Study: 3841206
Drug: Diflunisal 500
Normalized name: diflunisal 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 500 mg twice daily for 14 days
Study: 30959740
Drug: Synergy 1
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergy 1 (10 g per day)
Study: 30266885
Drug: Thrombolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis treatment in infratentorial AIS with baseline NIHSS score > 6
Study: 27143684
Drug: Outpatient intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient intensification of HF therapy
Study: 25585779
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) cream
Study: 3759280
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day metoprolol
Study: 18037099
Drug: C.E.R.A. (methoxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. (methoxy polyethylene glycol-epoetin beta) administered intravenously once every 2 weeks
Study: 18037099
Drug: Epoetin administered
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin administered 3 times weekly
Study: 16039618
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) with antidepressant medication (n = 17)
Study: 16039618
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication alone (n = 23)
Study: 11237351
Drug: 0.4% CMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% CMP solution
Study: 11237351
Drug: 2.0% CMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% CMP solution
Study: 11237351
Drug: Water containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water containing colorant and clouding agent
Study: 8297216
Drug: DMT 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT 0.05 mg/kg
Study: 8297216
Drug: DMT 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT 0.1 mg/kg
Study: 8297216
Drug: DMT 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT 0.2 mg/kg
Study: 8297216
Drug: DMT 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT 0.4 mg/kg
Study: 8297216
Drug: DMT (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT (all doses)
Study: 3671137
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml (5 mg) nebulized metaproterenol
Study: 3671137
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml nebulized metaproterenol
Study: 3671137
Drug: 0.3 ml
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml nebulized metaproterenol
Study: 3671137
Drug: 0.0 ml
Normalized name: ALCOHOL 6.3 mL in 10.0 mL TOPICAL SPRAY [Sanell Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 ml (placebo)
Study: 27446836
Drug: Split-dose PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose PEG lavage
Study: 27446836
Drug: Single 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 4 L PEG lavage
Study: 23809044
Drug: Increased urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urine cotinine (≥ 30 ng/mg creatinine)
Study: 21368757
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of gemfibrozil taken 0 hours before repaglinide
Study: 21368757
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of gemfibrozil taken 1 hour before repaglinide
Study: 21368757
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of gemfibrozil taken 3 hours before repaglinide
Study: 21368757
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of gemfibrozil taken 6 hours before repaglinide
Study: 21368757
Drug: Control: 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: 0.25 mg of repaglinide alone
Study: 19500860
Drug: Topical levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levobupivacaine (5 ml, 25 mg/10 ml)
Study: 19500860
Drug: Saline swabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline swabs (5 ml)
Study: 19500860
Drug: Topical levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levobupivacaine and saline swabs
Study: 8356895
Drug: Psychiatric day
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric day treatment
Study: 29781308
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone injection
Study: 28061430
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (once-daily)
Study: 25315404
Drug: Delayed-release DMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release DMF 240 mg PO BID
Study: 25315404
Drug: Delayed-release DMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release DMF 240 mg PO TID
Study: 17924779
Drug: Progesterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (100 mg to 300 mg twice daily for 9 weeks)
Study: 8630638
Drug: Intramuscular meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular meloxicam 15 mg for 7 days
Study: 8630638
Drug: Intramuscular piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular piroxicam 20 mg for 7 days
Study: 8630638
Drug: Intramuscular meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular meloxicam 15 mg
Study: 6391588
Drug: No behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: No behavioural treatment
Study: 30530801
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg (single agent)
Study: 30530801
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg plus rituximab 375 mg/m2
Study: 17174705
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion of 1 g pralidoxime over 1 hour every hour for 48 hours after a 2 g loading dose
Study: 17174705
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of 1 g pralidoxime over 1 hour every 4 hours for 48 hours after a 2 g loading dose
Study: 14577980
Drug: 4-mg nicotine
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg nicotine polacrilex lozenge
Study: 14577980
Drug: 2-mg nicotine
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg nicotine polacrilex lozenge
Study: 14577980
Drug: Lozenges administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenges administered every 90 min
Study: 14577980
Drug: 4-mg nicotine
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg nicotine polacrilex lozenge (used as directed)
Study: 10761819
Drug: Valerian extract
Normalized name: valerian extract
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian extract (multiple doses over 14 days)
Study: 1534646
Drug: SP (morphine‐scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP (morphine‐scopolamine + pancuronium)
Study: 1534646
Drug: SV (morphine‐scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SV (morphine‐scopolamine + vecuronium)
Study: 6374246
Drug: Intravenous instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous instillation of sodium nitroprusside (39 patients)
Study: 6374246
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (17 patients)
Study: 22952580
Drug: 8 days
Normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 days of antibiotic treatment
Study: 22952580
Drug: 15 days
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 days of antibiotic treatment
Study: 17386350
Drug: telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 80 mg/amlodipine 2.5 mg daily
Study: 17386350
Drug: telmisartan 120
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telmisartan 120 mg/amlodipine 2.5 mg daily
Study: 17386350
Drug: telmisartan 160
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telmisartan 160 mg/amlodipine 2.5 mg daily
Study: 17386350
Drug: amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5 mg/telmisartan 40 mg daily
Study: 17386350
Drug: amlodipine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 7.5 mg/telmisartan 40 mg daily
Study: 17386350
Drug: amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 10 mg/telmisartan 40 mg daily
Study: 29974571
Drug: Self-administered misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered misoprostol (S-Mis)
Study: 29974571
Drug: Hospital-administered misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hospital-administered misoprostol (H-Mis)
Study: 28923084
Drug: TG4010 with
Normalized name: TG4010
DrugBank: TG4010 (DB06584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4010 with standard chemotherapy
Study: 26362774
Drug: 10mg oral
Normalized name: OPIPZA 10mg Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg oral dose of THCv
Study: 23220014
Drug: Hemoglobin threshold
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin threshold of 120 g/L (experimental arm)
Study: 23220014
Drug: Hemoglobin threshold
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin threshold of 70 g/L (control arm)
Study: 18294232
Drug: Immediately Loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately Loaded (IL) implants
Study: 18294232
Drug: Conventionally Loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally Loaded (CL) implants
Study: 10984013
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sodium valproate
Study: 10984013
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg sodium valproate
Study: 10984013
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg sodium valproate
Study: 10984013
Drug: 100 mg,
Normalized name: CoQmax Omega 100 mg, 500 mg-100 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, 150 mg, and 300 mg sodium valproate
Study: 8105943
Drug: 2.5 mEq/L
Normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mEq/L calcium dialysate with oral calcitriol (median dose 0.25 microgram/day)
Study: 8105943
Drug: 3.5 mEq/L
Normalized name: bicarb dialy soln 7-no pot,dex calcium (3.5 mEq/L)-magnesium (1 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mEq/L calcium dialysate without calcitriol
Study: 8105943
Drug: 2.5 mEq/L
Normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mEq/L calcium dialysate with oral calcitriol
Study: 21556830
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei treatment for 3 months
Study: 30268262
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no probiotic treatment)
Study: 19236785
Drug: supporting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: supporting treatment
Study: 18001447
Drug: Intramuscular methylergometrine
Normalized name: methylergometrine
DrugBank: Methylergometrine (DB00353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylergometrine
Study: 15021279
Drug: Buprenorphine-soaked absorbable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-soaked absorbable gelatin sponge (0.3 mg buprenorphine diluted to 5 mL with normal saline)
Study: 15021279
Drug: Absorbable gelatin
Normalized name: Absorbable gelatin film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable gelatin sponge soaked with 5 mL normal saline (control group)
Study: 12492609
Drug: Intravenous urotensin
Normalized name: neurotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urotensin II infusion at 300 pmol min‐1
Study: 12492609
Drug: Intravenous urotensin
Normalized name: neurotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urotensin II infusion